Tectonic Therapeutic Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Watertown, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2018-06-21. Tectonic Therapeutic, Inc. is a biotechnology company. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).

Рейтинг Tectonic

Откройте для себя компании с высоким рейтингом